These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 35155620)

  • 21. Comparing newer oral anti-platelets prasugrel and ticagrelor in reduction of ischemic events-evidence from a network meta-analysis.
    Chatterjee S; Ghose A; Sharma A; Guha G; Mukherjee D; Frankel R
    J Thromb Thrombolysis; 2013 Oct; 36(3):223-32. PubMed ID: 23212803
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effects of L-carnitine supplementation on indicators of inflammation and oxidative stress: a systematic review and meta-analysis of randomized controlled trials.
    Fathizadeh H; Milajerdi A; Reiner Ž; Amirani E; Asemi Z; Mansournia MA; Hallajzadeh J
    J Diabetes Metab Disord; 2020 Dec; 19(2):1879-1894. PubMed ID: 33520867
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The risk of dyspnea in patients treated with third-generation P2Y
    Zhang N; Xu W; Li O; Zhang B
    BMC Cardiovasc Disord; 2020 Mar; 20(1):140. PubMed ID: 32183711
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Effects of Vitamin D Supplementation on Glycemic Control, Lipid Profiles and C-Reactive Protein Among Patients with Cardiovascular Disease: a Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Ostadmohammadi V; Milajerdi A; Ghayour-Mobarhan M; Ferns G; Taghizadeh M; Badehnoosh B; Mirzaei H; Asemi Z
    Curr Pharm Des; 2019; 25(2):201-210. PubMed ID: 30854952
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of clopidogrel versus prasugrel and ticagrelor for coronary artery disease treatment in patients with CYP2C19 LoF alleles: a systemic review and meta-analysis.
    Yoon HY; Lee N; Seong JM; Gwak HS
    Br J Clin Pharmacol; 2020 Aug; 86(8):1489-1498. PubMed ID: 32320492
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk of bradyarrhythmia related to ticagrelor: A systematic review and meta-analysis.
    Pujade I; Perino J; Mathieu C; Arnaud M; Raschi E; Gatti M; Bezin J; Salvo F
    Pharmacol Res; 2020 Oct; 160():105089. PubMed ID: 32687950
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antiplatelet agents for preventing vaso-occlusive events in people with sickle cell disease: a systematic review.
    Martí-Carvajal A; Abd El Aziz MA; Martí-Amarista C; Solà I
    Clin Adv Hematol Oncol; 2019 Apr; 17(4):234-243. PubMed ID: 31188815
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adverse clinical outcomes associated with double dose clopidogrel compared to the other antiplatelet regimens in patients with coronary artery disease: a systematic review and meta-analysis.
    Zhuo X; Zhuo B; Ouyang S; Niu P; Xiao M
    BMC Pharmacol Toxicol; 2018 Sep; 19(1):54. PubMed ID: 30176938
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative Efficacy and Safety of Oral P2Y
    Navarese EP; Khan SU; Kołodziejczak M; Kubica J; Buccheri S; Cannon CP; Gurbel PA; De Servi S; Budaj A; Bartorelli A; Trabattoni D; Ohman EM; Wallentin L; Roe MT; James S
    Circulation; 2020 Jul; 142(2):150-160. PubMed ID: 32468837
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Switching to Clopidogrel in Patients With Acute Coronary Syndrome Managed With Percutaneous Coronary Intervention Initially Treated With Prasugrel or Ticagrelor: Systematic Review and Meta-analysis.
    Hong J; Turgeon RD; Pearson GJ
    Ann Pharmacother; 2019 Oct; 53(10):997-1004. PubMed ID: 30999764
    [No Abstract]   [Full Text] [Related]  

  • 31. Efficacy and Safety of High Potent P2Y
    Schreuder MM; Badal R; Boersma E; Kavousi M; Roos-Hesselink J; Versmissen J; Visser LE; Roeters van Lennep JE
    J Am Heart Assoc; 2020 Feb; 9(4):e014457. PubMed ID: 32063118
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effects of carnitine supplementation on clinical characteristics of patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials.
    Abolfathi M; Mohd-Yusof BN; Hanipah ZN; Mohd Redzwan S; Yusof LM; Khosroshahi MZ
    Complement Ther Med; 2020 Jan; 48():102273. PubMed ID: 31987257
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of niacin on endothelial function: a systematic review and meta-analysis of randomized controlled trials.
    Sahebkar A
    Vasc Med; 2014 Feb; 19(1):54-66. PubMed ID: 24391126
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ticagrelor as compared to conventional antiplatelet agents in coronary artery disease: A comprehensive meta-analysis of 15 randomized trials.
    Verdoia M; Savonitto S; Dudek D; Kedhi E; De Luca G
    Vascul Pharmacol; 2021 Apr; 137():106828. PubMed ID: 33385541
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of antiplatelet drug on coronary endothelial and microvascular function: comparison with ticagrelor and clopidogrel.
    Choi WG; Kim GC; Lee CH; Kim HY; Kim DW
    Korean J Intern Med; 2021 Mar; 36(2):352-361. PubMed ID: 32564571
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Thiazolidinediones improve flow-mediated dilation: a meta-analysis of randomized clinical trials.
    Stojanović M; Prostran M; Radenković M
    Eur J Clin Pharmacol; 2016 Apr; 72(4):385-98. PubMed ID: 26690770
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Network meta-analysis of prasugrel, ticagrelor, high- and standard-dose clopidogrel in patients scheduled for percutaneous coronary interventions.
    Steiner S; Moertl D; Chen L; Coyle D; Wells GA
    Thromb Haemost; 2012 Aug; 108(2):318-27. PubMed ID: 22627948
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outcome of intracranial flow diversion according to the antiplatelet regimen used: a systematic review and meta-analysis.
    Podlasek A; Al Sultan AA; Assis Z; Kashani N; Goyal M; Almekhlafi MA
    J Neurointerv Surg; 2020 Feb; 12(2):148-155. PubMed ID: 31273075
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prasugrel vs Ticagrelor for DAPT in Patients with ACS Undergoing PCI: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Al-Abdouh A; Barbarawi M; Abusnina W; Amr M; Zhao D; Savji N; Hasan RK; Michos ED
    Cardiovasc Revasc Med; 2020 Dec; 21(12):1613-1618. PubMed ID: 32513604
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Head-to-head comparison of prasugrel versus ticagrelor in patients undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials.
    Sakurai R; Burazor I; Bonneau HN; Kaneda H
    J Interv Cardiol; 2017 Oct; 30(5):457-464. PubMed ID: 28804959
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.